Direction, evidence grade, and study type are AI-generated labels (gpt-5-mini), not human-verified. Syntheses are LLM-written. "Tensions" are machine-detected candidates, not confirmed contradictions. A research-acceleration tool, not peer review.
How this is built →
1Distinct papers
0Unique collaborators
1/1OpenAlex citation coverage
Publication dates unavailable. Corpus fetch span: 2026.
Identity provenance
Provider IDs
- Openalex:
A5094924422
ORCID evidence
No valid ORCID is stored.
Observed aliases (2)
- Rolando Pajon (openalex, provider refresh)
- Rolando Pajón (openalex, provider refresh)
Topics and outcomes in this view
Assessment themes
- Adoption: 1 paper
- Governance: 1 paper
- Innovation: 1 paper
- Productivity: 1 paper
- Skills Training: 1 paper
Claim outcomes
- Research Productivity: 1 paper
- Adoption Rate: 1 paper
- Organizational Efficiency: 1 paper
- Governance And Regulation: 1 paper
- Market Structure: 1 paper
- Ai Safety And Ethics: 1 paper
- Developer Productivity: 1 paper
- Inequality: 1 paper
- Innovation Output: 1 paper
- Regulatory Compliance: 1 paper
- Skill Acquisition: 1 paper
Papers in the OpenAlex view
Latest stored OpenAlex author observations only. Citation counts below are from the same provider and are not combined with other services.
Scroll the table horizontally to see every column.
| Paper | Author evidence | Date | Provider citations |
|---|---|---|---|
| AI promises faster, cheaper drug discovery but gains are conditional: large firms adopt via partnerships, cultural transformation, or productionized tools while startups exploit pre‑trained models and cloud services, yet durable democratized discovery hinges on interoperable data, robust validation, skilled teams and regulatory clarity.semantic_scholar | Rolando Pajon provider id |
Fetched 2026-03-18 | 0 |
Citation observation summary
OpenAlex supplied counts for 1 of 1 papers in this view; 0 are missing. The observed paper counts sum to 0 cumulative citations. This is a coverage summary, not an author score or h-index.